Charles A. Signorino, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Charles A. Signorino, PhD


Charles A. Signorino, PhD is a Pharmtech editorial advisory board (EAB) member

Charles A. Signorino, PhD
CEO
Emerson Resources, Inc.

Charles A. Signorino is the chief executive officer of Emerson Resources, Inc. He is an adjunct professor of pharmaceutics at the University of the Sciences in Philadelphia, and he has held positions at CS Associates Inc., Colorcon Inc., Eastern College, and Arco Chemical. His areas of expertise are aqueous enteric and film coating technology, FDA-approved colors and applications, pharmaceutical excipients, and rapid sugar coating.

Signorino is a member of the American Association of Pharmaceutical Scientists (AAPS), the American Chemical Society (ACS), and is also a member of the editorial advisory board for American Pharmaceutical Review. He has authored numerous technical publications, and he has given numerous seminars for various industry and academic events.

Signorino holds a BS from Pennsylvania State University, an MS and PhD from the University of Pennsylvania and an MAR from Westminster Theological Seminary.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here